Market closedNon-fractional
GH Research/GHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
Ticker
GHRS
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
49
Website
www.ghres.com
GH Research Metrics
BasicAdvanced
$627M
Market cap
-
P/E ratio
-$0.62
EPS
0.80
Beta
-
Dividend rate
Price and volume
Market cap
$627M
Beta
0.8
Financial strength
Current ratio
22.059
Quick ratio
21.699
Long term debt to equity
0.267
Total debt to equity
0.428
Interest coverage (TTM)
-57.57%
Management effectiveness
Return on assets (TTM)
-11.27%
Return on equity (TTM)
-14.31%
Valuation
Price to book
2.99
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
-17.348
Growth
Earnings per share change (TTM)
16.95%
3-year earnings per share growth
125.14%
What the Analysts think about GH Research
Analyst Ratings
Majority rating from 5 analysts.
GH Research Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
100.00%
Profit margin
0.00%
NaN%
GH Research Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.15
-$0.11
-$0.21
-$0.15
-
Expected
-$0.25
-$0.20
-$0.20
-$0.22
-$0.23
Surprise
-40.81%
-44.78%
3.35%
-32.07%
-
GH Research News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GH Research stock?
GH Research (GHRS) has a market cap of $627M as of July 05, 2024.
What is the P/E ratio for GH Research stock?
The price to earnings (P/E) ratio for GH Research (GHRS) stock is 0 as of July 05, 2024.
Does GH Research stock pay dividends?
No, GH Research (GHRS) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next GH Research dividend payment date?
GH Research (GHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for GH Research?
GH Research (GHRS) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell GH Research stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.